
|Videos|August 17, 2011
Dr. Reckamp Discusses Heat Shock Proteins in Lung Cancer
Author(s)Karen Reckamp, MD
Dr. Karen Reckamp from City of Hope Cancer center Discusses Heat Shock Proteins in Lung Cancer
Advertisement
Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, discusses the use of heat shock proteins in the treatment of lung cancer.
Reckamp explains that heat shock proteins act as chaperone proteins that permit oncoproteins to function. The proteins work as an alternative to inhibiting the tyrosine kinase pathway and are involved in multiple lung cancer related signalling pathways such as EGFR, RAS, ALK, and MET. Heat shock proteins can be used when resistance to other methods are developed.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Targeted Therapies, Frontline Combos Headline Key Lung Cancer Data to Emerge From ASCO 2026
4
CARTITUDE-4 Analysis Shows Bridging Therapy Response Predicts Cilta-Cel Benefit in Lenalidomide-Refractory Myeloma
5






































































